Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-TECHNE CorpTECH · Entity 3479 | Director · Chief Executive Officer | August 15, 2023 | August 17, 2023 |
| Gentherm IncTHRM · Entity 4845 | Director | May 14, 2026 | May 15, 2026 |
| Orthofix Medical Inc.OFIX · Entity 1975 | Director | June 10, 2026 | June 12, 2026 |
| Quantum-Si IncQSI · Entity 6440 | Director | May 18, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-TECHNE Corp
Report date August 15, 2023 · Filed August 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,278,269 |
Last balance in matching sequence
After 2023-08-15 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2023-08-15 · Exercise / conversion · Acquired 17,632 · Balance 1,286,944 F1: Includes 7,128 shares of restricted stock for which the risk of forfeiture will lapse on August 6, 2024. Row 2 · 2023-08-15 · Tax withholding · Disposed 8,675 · Balance 1,278,269 F1: Includes 7,128 shares of restricted stock for which the risk of forfeiture will lapse on August 6, 2024. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 59,095 |
Reported balance
After 2023-08-15 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2023-08-15 · Grant · Acquired 59,095 · Balance 59,095 F3: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9: 19,698 shares vest on each of 8/15/2024 and 8/15/2026, and 19,699 shares vest on 8/15/2025. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 35,268 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 35,268 F3: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F4: 17,636 shares vest on 8/15/2024 and 17,632 shares vest on 8/15/2025. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 32,064 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 32,064 F3: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F6: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Common StockSEC Table I · non-derivative | IndirectBy Step-Son | 400 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 400 |
| Common StockSEC Table I · non-derivative | IndirectBy Step-Daughter | 400 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 400 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.26 · Expires 2024-08-09 | Direct | 779,084 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 779,084 F2: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.33 · Expires 2025-08-08 | Direct | 361,336 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 361,336 F2: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.33 · Expires 2025-08-08 | Direct | 240,888 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 240,888 F2: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.60 · Expires 2026-08-07 | Direct | 342,900 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 342,900 F2: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.60 · Expires 2026-08-07 | Direct | 228,600 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 228,600 F2: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.97 · Expires 2027-08-05 | Direct | 66,600 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 66,600 F2: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.97 · Expires 2027-08-05 | Direct | 299,768 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 299,768 F2: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.97 · Expires 2027-08-05 | Direct | 153,180 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 153,180 F5: Options to purchase 38,292 shares vest on 8/5/21 and options to purchase 38,296 shares vest on each of 8/5/22, 8/5/23 and 8/5/24. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $120.46 · Expires 2028-08-06 | Direct | 125,260 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance 125,260 F6: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $120.46 · Expires 2028-08-06 | Direct | 83,504 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · Balance 83,504 F7: Options to purchase 20,876 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $94.52 · Expires 2029-08-15 | Direct | 600,000 |
Reported balance
Holding disclosure · report date 2023-08-15 · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · Balance 600,000 F8: 600,000 options vest in full or in part on 7/1/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 7,128 shares of restricted stock for which the risk of forfeiture will lapse on August 6, 2024.
F2: Fully exercisable.
F3: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F4: 17,636 shares vest on 8/15/2024 and 17,632 shares vest on 8/15/2025.
F5: Options to purchase 38,292 shares vest on 8/5/21 and options to purchase 38,296 shares vest on each of 8/5/22, 8/5/23 and 8/5/24.
F6: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F7: Options to purchase 20,876 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025.
F8: 600,000 options vest in full or in part on 7/1/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F9: 19,698 shares vest on each of 8/15/2024 and 8/15/2026, and 19,699 shares vest on 8/15/2025.
Gentherm Inc
Report date May 14, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,937 |
Reported balance
After 2026-05-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 4,292 · Balance 25,937 F1: The shares represent Restricted Common Stock issued under the 2023 Equity Incentive Plan that has been granted to the Reporting Person as compensation for serving on the Gentherm Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares represent Restricted Common Stock issued under the 2023 Equity Incentive Plan that has been granted to the Reporting Person as compensation for serving on the Gentherm Board of Directors.
Orthofix Medical Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 76,305 |
Reported balance
After 2026-06-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 14,965 · Balance 76,305 F1: Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer. F2: Includes 42,343 previously reported deferred stock units and an aggregate of 2,103 shares acquired under Orthofix's Stock Purchase Plan ("Orthofix's SPP") on 10/31/2025 and 4/30/2026. Orthofix's SPP is a "Stock Purchase Plan" as defined in Rule 16b-3(b)(5), and share acquisitions under the plan are exempt from Section 16(b). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer.
F2: Includes 42,343 previously reported deferred stock units and an aggregate of 2,103 shares acquired under Orthofix's Stock Purchase Plan ("Orthofix's SPP") on 10/31/2025 and 4/30/2026. Orthofix's SPP is a "Stock Purchase Plan" as defined in Rule 16b-3(b)(5), and share acquisitions under the plan are exempt from Section 16(b).
Quantum-Si Inc
Report date May 18, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.85 · Expires 2036-05-18 | Direct | 251,185 |
Reported balance
After 2026-05-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-18 · Grant · Acquired 251,185 · Balance 251,185 F1: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to continued service through the applicable vesting date. |
| Class A Common StockSEC Table I · non-derivative | Direct | 855,000 |
Reported balance
Holding disclosure · report date 2026-05-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 855,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to continued service through the applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SPARTON CORP
Report date March 04, 2019 · Filed March 04, 2019
Section 16 reporting ended · disclosed 2019-03-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-03-04 transaction · row 1
1 source rowRow 1 · 2019-03-04 · Disposition to issuer · Disposed 16,197 · Balance 0 F1: Disposed of pursuant to Agreement and Plan of Merger dated as of December 11, 2018, by and among Sparton Corporation, Sparton Parent, Inc. and Striker Merger Sub 2018, Inc. in exchange for $18.50 per share in cash, without interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to Agreement and Plan of Merger dated as of December 11, 2018, by and among Sparton Corporation, Sparton Parent, Inc. and Striker Merger Sub 2018, Inc. in exchange for $18.50 per share in cash, without interest.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2021 Filed Sep 7, 2021 21:00 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 73,492 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0000914190-21-000360 · edgar.xml · derivative · entry 5 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,450 Underlying: Common Stock · 73,492 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:00 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 42,005 | $510.78 | $21,455,313.90 |
DisclosureSEC source: 0000914190-21-000360 · edgar.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,601 F1 · balance_after: Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:00 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 73,492 | $108.49 | $7,973,147.08 |
DisclosureSEC source: 0000914190-21-000360 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,606 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| August 11, 2021 Filed Aug 13, 2021 20:03 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 921 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0000914190-21-000260 · edgar.xml · derivative · entry 4 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,942 Underlying: Common Stock · 921 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 11, 2021 Filed Aug 13, 2021 20:03 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 921 | $108.49 | $99,919.29 |
DisclosureSEC source: 0000914190-21-000260 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,114 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:22 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 20,876 | $0.00 Strike: $481.82 | $0.00 |
DisclosureSEC source: 0000914190-21-000217 · edgar.xml · derivative · entry 25 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,876 Underlying: Common Stock · 20,876 shares Expires 2028-08-06 F13 · derivative.exercise_date: Options to purchase 5,219 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:22 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 31,315 | $0.00 Strike: $481.82 | $0.00 |
DisclosureSEC source: 0000914190-21-000217 · edgar.xml · derivative · entry 24 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,315 Underlying: Common Stock · 31,315 shares Expires 2028-08-06 F12 · derivative.exercise_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:22 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 8,016 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000217 · edgar.xml · derivative · entry 23 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,016 Underlying: Common Stock · 8,016 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F12 · derivative.exercise_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F12 · derivative.expiration_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:22 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 16,918 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000217 · edgar.xml · derivative · entry 12 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,918 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F4 · derivative.exercise_date: Vested in full on 8/8/2021 upon the certification of achievement of performance goals. F4 · derivative.expiration_date: Vested in full on 8/8/2021 upon the certification of achievement of performance goals. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:22 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 12,475 | $481.82 | $6,010,704.50 |
DisclosureSEC source: 0000914190-21-000217 · edgar.xml · nonDerivative · entry 3 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,193 F1 · balance_after: Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:22 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 16,918 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000217 · edgar.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,668 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:22 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 5,344 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000217 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,750 F1 · balance_after: Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 20:36 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 326 | $450.37 | $146,820.62 |
DisclosureSEC source: 0000914190-21-000187 · edgar.xml · nonDerivative · entry 6 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,406 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $450.37 to $450.625, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 20:36 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 2,583 | $449.09 | $1,159,999.47 |
DisclosureSEC source: 0000914190-21-000187 · edgar.xml · nonDerivative · entry 5 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,732 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $449.00 to $449.63, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:36 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 109 | $452.13 | $49,282.17 |
DisclosureSEC source: 0000914190-21-000187 · edgar.xml · nonDerivative · entry 4 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,315 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F3 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:36 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,050 | $451.54 | $474,117.00 |
DisclosureSEC source: 0000914190-21-000187 · edgar.xml · nonDerivative · entry 3 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,424 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $451.02 to $452.02, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:36 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,698 | $450.39 | $764,762.22 |
DisclosureSEC source: 0000914190-21-000187 · edgar.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,474 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $450.075 to $450.95, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:36 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 6,732 | $449.35 | $3,025,024.20 |
DisclosureSEC source: 0000914190-21-000187 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,172 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $449.00 to $449.94, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 23:22 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 349 | $450.10 | $157,084.90 |
DisclosureSEC source: 0000914190-21-000185 · edgar.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,904 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F3 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 23:22 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 7,132 | $449.10 | $3,202,981.20 |
DisclosureSEC source: 0000914190-21-000185 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,253 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $449.00 to $449.97, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:25 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 36,849 | $0.00 Strike: $94.35 | $0.00 |
DisclosureSEC source: 0000914190-21-000165 · edgar.xml · derivative · entry 5 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,849 shares Expires 2021-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:25 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 21,305 | $420.12 | $8,950,656.60 |
DisclosureSEC source: 0000914190-21-000165 · edgar.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,385 F1 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:25 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 36,849 | $94.35 | $3,476,703.15 |
DisclosureSEC source: 0000914190-21-000165 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| May 20, 2021 Filed May 24, 2021 19:48 UTC | Gentherm Inc THRM · Entity 4845 | GrantCommon Stock | 1,422 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-035287 · doc4.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,061 F1 · security: The shares represent Restricted Common Stock issued under the 2013 Equity Incentive Plan that has been granted to the Reporting Person as compensation for serving on the Gentherm Board of Directors. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:38 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $94.35 | $0.00 |
DisclosureSEC source: 0000914190-21-000067 · edgar.xml · derivative · entry 5 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,849 Underlying: Common Stock · 30,000 shares Expires 2021-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:38 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 17,428 | $411.00 | $7,162,908.00 |
DisclosureSEC source: 0000914190-21-000067 · edgar.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,841 F1 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:38 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 30,000 | $94.35 | $2,830,500.00 |
DisclosureSEC source: 0000914190-21-000067 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,269 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 21:42 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 20,000 | $344.00 | $6,880,000.00 |
DisclosureSEC source: 0000914190-21-000014 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,269 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2020. F2 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| December 07, 2020 Filed Dec 9, 2020 21:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 5,000 | $308.00 | $1,540,000.00 |
DisclosureSEC source: 0000914190-20-000444 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,269 F1 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 23:04 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 25,157 | $0.00 Strike: $86.25 | $0.00 |
DisclosureSEC source: 0000914190-20-000399 · edgar.xml · derivative · entry 5 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,157 shares Expires 2021-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 23:04 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 15,375 | $302.47 | $4,650,476.25 |
DisclosureSEC source: 0000914190-20-000399 · edgar.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,269 F1 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 23:04 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 25,157 | $86.25 | $2,169,791.25 |
DisclosureSEC source: 0000914190-20-000399 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| August 09, 2020 Filed Aug 11, 2020 22:20 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 21,291 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-20-000289 · edgar.xml · derivative · entry 11 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,291 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F5 · derivative.exercise_date: On 8/9/2020, the Board of Directors certified vesting of 21,291 performance RSUs. F5 · derivative.expiration_date: On 8/9/2020, the Board of Directors certified vesting of 21,291 performance RSUs. Read SEC document |
| August 09, 2020 Filed Aug 11, 2020 22:20 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 12,287 | $265.76 | $3,265,393.12 |
DisclosureSEC source: 0000914190-20-000289 · edgar.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,487 F1 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| August 09, 2020 Filed Aug 11, 2020 22:20 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 21,291 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-20-000289 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 23:07 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 16,650 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000253 · edgar.xml · derivative · entry 23 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,650 Underlying: Common Stock · 16,650 shares Expires 2027-08-05 F14 · derivative.exercise_date: Options to purchase 5,550 shares vest on each of 8/5/21, 8/5/22 and 8/5/23. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 23:07 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 16,650 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000253 · edgar.xml · derivative · entry 22 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,650 Underlying: Common Stock · 16,650 shares Expires 2027-08-05 F13 · derivative.exercise_date: Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021 Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 23:07 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 38,295 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000253 · edgar.xml · derivative · entry 21 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,295 Underlying: Common Stock · 38,295 shares Expires 2027-08-05 F12 · derivative.exercise_date: Options to purchase 9,574 shares vest on each of 8/5/21, 8/5/22 and 8/5/23 and options to purchase 9,573 shares vest on 8/5/24. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 23:07 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 57,442 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000253 · edgar.xml · derivative · entry 20 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,442 Underlying: Common Stock · 57,442 shares Expires 2027-08-05 F11 · derivative.exercise_date: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 23:07 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 12,879 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-20-000253 · edgar.xml · derivative · entry 19 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,879 Underlying: Common Stock · 12,879 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11 · derivative.exercise_date: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F11 · derivative.expiration_date: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 23:07 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 8,586 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-20-000253 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,483 F1 · balance_after: Includes (i) 4,732 shares of restricted stock for which the risk of forfeiture will lapse on August 9, 2020; (ii) 7,519 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2020 and as to 3,759 shares on August 8, 2021; (iii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iv) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| May 26, 2020 Filed May 28, 2020 21:41 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 21,159 | $0.00 Strike: $86.25 | $0.00 |
DisclosureSEC source: 0000914190-20-000186 · edgar.xml · derivative · entry 5 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,157 Underlying: Common Stock · 21,159 shares Expires 2021-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 26, 2020 Filed May 28, 2020 21:41 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 13,018 | $266.40 | $3,467,995.20 |
DisclosureSEC source: 0000914190-20-000186 · edgar.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,130 F1 · balance_after: Includes (i) 4,732 shares of restricted stock for which the risk of forfeiture will lapse on August 9, 2020; (ii) 7,519 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2020 and as to 3,759 shares on August 8, 2021; and (iii) 11,291 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on each of August 7, 2020 and August 7, 2021 and as to 3,763 shares on August 7, 2022. Read SEC document |
| May 26, 2020 Filed May 28, 2020 21:41 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 21,159 | $86.25 | $1,824,963.75 |
DisclosureSEC source: 0000914190-20-000186 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 4,732 shares of restricted stock for which the risk of forfeiture will lapse on August 9, 2020; (ii) 7,519 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2020 and as to 3,759 shares on August 8, 2021; and (iii) 11,291 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on each of August 7, 2020 and August 7, 2021 and as to 3,763 shares on August 7, 2022. Read SEC document |
| May 21, 2020 Filed May 26, 2020 20:31 UTC | Gentherm Inc THRM · Entity 4845 | GrantCommon Stock | 4,467 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-032018 · doc4.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,639 F1 · security: The shares represent Restricted Common Stock issued under the 2013 Equity Incentive Plan that has been granted to the Reporting Person as compensation for serving on the Gentherm Board of Directors. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 21:34 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,276 | $0.00 Strike: $67.46 | $0.00 |
DisclosureSEC source: 0000914190-20-000018 · edgar.xml · derivative · entry 5 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 Underlying: Common Stock · 10,276 shares Expires 2020-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 21:34 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 10,276 | $217.28 | $2,232,769.28 |
DisclosureSEC source: 0000914190-20-000018 · edgar.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,989 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2019 and amended on June 7, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.00 to $217.83, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: Includes (i) 4,732 shares of restricted stock for which the risk of forfeiture will lapse on August 9, 2020; (ii) 7,519 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2020 and as to 3,759 shares on August 8, 2021; and (iii) 11,291 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on each of August 7, 2020 and August 7, 2021 and as to 3,763 shares on August 7, 2022. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 21:34 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 10,276 | $67.46 | $693,218.96 |
DisclosureSEC source: 0000914190-20-000018 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 4,732 shares of restricted stock for which the risk of forfeiture will lapse on August 9, 2020; (ii) 7,519 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2020 and as to 3,759 shares on August 8, 2021; and (iii) 11,291 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on each of August 7, 2020 and August 7, 2021 and as to 3,763 shares on August 7, 2022. Read SEC document |
| January 03, 2020 Filed Jan 6, 2020 21:39 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 7,999 | $0.00 Strike: $67.46 | $0.00 |
DisclosureSEC source: 0000914190-20-000014 · edgar.xml · derivative · entry 13 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,376 Underlying: Common Stock · 7,999 shares Expires 2020-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully exercisable. Read SEC document |
| January 03, 2020 Filed Jan 6, 2020 21:39 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,741 | $218.23 | $379,938.43 |
DisclosureSEC source: 0000914190-20-000014 · edgar.xml · nonDerivative · entry 9 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,989 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2019 and amended on June 7, 2019. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.02 to $218.54, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: Includes (i) 4,732 shares of restricted stock for which the risk of forfeiture will lapse on August 9, 2020; (ii) 7,519 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2020 and as to 3,759 shares on August 8, 2021; and (iii) 11,291 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on each of August 7, 2020 and August 7, 2021 and as to 3,763 shares on August 7, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.